RT @JACCJournals: The related #JACCCardioOnc resource, "Immune Checkpoint Inhibitor-Related Adverse CV Events in Patients With #LungCancer"…
RT @JACCJournals: The related #JACCCardioOnc resource, "Immune Checkpoint Inhibitor-Related Adverse CV Events in Patients With #LungCancer"…
RT @JACCJournals: The related #JACCCardioOnc resource, "Immune Checkpoint Inhibitor-Related Adverse CV Events in Patients With #LungCancer"…
The related #JACCCardioOnc resource, "Immune Checkpoint Inhibitor-Related Adverse CV Events in Patients With #LungCancer" mentioned by Dr. Christine Cambareri, can be found here: https://t.co/9PnvW3ORW3 #CardioOnc #ACCEd #CardioTwitter https://t.co/N0OAL
RT @JACCJournals: Dr. Christine Cambareri's related #JACCCardioOnc resource on #lungcancer, "Immune Checkpoint Inhibitor-Related Adverse CV…
Dr. Christine Cambareri's related #JACCCardioOnc resource on #lungcancer, "Immune Checkpoint Inhibitor-Related Adverse CV Events in Patients With Lung Cancer" can be found here: https://t.co/9PnvW3ORW3 #CardioOnc #ACCEd #CardioTwitter https://t.co/1h9FPR
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
RT @OncoCard_Ganken: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in P... https://t.co/ulJ4LOsqR6 ICI-associated card…
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in P... https://t.co/ulJ4LOsqR6 ICI-associated cardiotoxicity was associated with elevations in serum troponin and BNP, and combined immunotherapy with VEGFIs or TKIs. #LungCancer #ICI #MA
RT @ELS_Cardiology: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa…
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/xWJ13BybJa #SoMe #medtwitter #MedEd @JACCJournals https://t.co/KD7H4lYibI
RT @OncologyAdvance: Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/m5pP7tFCQ6…
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/m5pP7tFCQ6 #SoMe #medtwitter #MedEd @JACCJournals https://t.co/alijf6zX1d
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.co/7IRHGM9z1b #SoMe #medtwitter #MedEd https://t.co/mTxksxeWop
RT @CampbellMDPhD: "ICI-associated cardiotoxicity was associated with elevations in serum troponin and BNP, and combined immunotherapy with…
"ICI-associated cardiotoxicity was associated with elevations in serum troponin and BNP, and combined immunotherapy with VEGFIs or TKIs." in @JACCJournals https://t.co/dXeCNmSjGY #CardioOnc #cardiotwitter https://t.co/tujNy45a5o
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
RT @JACCJournals: In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV ev…
In a single center study of #lungcancer pts treated w/ immune checkpoint inhibitors, the incidence of major adverse CV events was 13.3%. Read more stats from Drs. @bhtrachtenberg, @KalChitturi, @mahwash_kassi & @HMethodistCV colleagues in #JACCCardioOn
Great collaboration from our cardiovascular team finding that ICIs were not independently associated with an increased risk of MACE in patients with #lungcancer: https://t.co/lkbxQjP1P6 #LCSM @bhtrachtenberg @hfdocbhimaraj
RT @bhtrachtenberg: Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients;…
RT @bhtrachtenberg: Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients;…
RT @bhtrachtenberg: Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients;…
RT @bhtrachtenberg: Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients;…
Our paper published today in JACCCO# found an increased risk of MACE with ICI + elevated biomarkers and ICI + VEGFI/TKI in patients with lung cancer. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer https://t.
RT @bhtrachtenberg: Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients;…
Our @MethodistHosp experience led by future cardio-oncology star @KalChitturi with Immune CPI in lung cancer patients; association of CV events with biomarker elevation and possibly with concomitant TKI/VEGF Rx https://t.co/r8pmg7XLLo #cardioOnc